Department of Medical Oncology, Amsterdam University Medical Center (UMC) location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands.
Front Immunol. 2024 Apr 4;15:1372272. doi: 10.3389/fimmu.2024.1372272. eCollection 2024.
Tumors in the distal esophagus (EAC), gastro-esophageal junction including cardia (GEJAC), and stomach (GAC) develop in close proximity and show strong similarities on a molecular and cellular level. However, recent clinical data showed that the effectiveness of chemo-immunotherapy is limited to a subset of GEAC patients and that EACs and GEJACs generally benefit less from checkpoint inhibition compared to GACs. As the composition of the tumor immune microenvironment drives response to (immuno)therapy we here performed a detailed immune analysis of a large series of GEACs to facilitate the development of a more individualized immunomodulatory strategy.
Extensive immunophenotyping was performed by 14-color flow cytometry in a prospective study to detail the immune composition of untreated gastro-esophageal cancers (n=104) using fresh tumor biopsies of 35 EACs, 38 GEJACs and 31 GACs. The immune cell composition of GEACs was characterized and correlated with clinicopathologic features such as tumor location, MSI and HER2 status. The spatial immune architecture of a subset of tumors (n=30) was evaluated using multiplex immunohistochemistry (mIHC) which allowed us to determine the tumor infiltration status of CD3+, CD8+, FoxP3+, CD163+ and Ki67+ cells.
Immunophenotyping revealed that the tumor immune microenvironment of GEACs is heterogeneous and that immune suppressive cell populations such as monocytic myeloid-derived suppressor cells (mMDSC) are more abundant in EACs compared to GACs (p<0.001). In contrast, GACs indicated a proinflammatory microenvironment with elevated frequencies of proliferating (Ki67+) CD4 Th cells (p<0.001), Ki67+ CD8 T cells (p=0.002), and CD8 effector memory-T cells (p=0.024). Differences between EACs and GACs were confirmed by mIHC analyses showing lower densities of tumor- and stroma-infiltrating Ki67+ CD8 T cells in EAC compared to GAC (both p=0.021).
This comprehensive immune phenotype study of a large series of untreated GEACs, identified that tumors with an esophageal tumor location have more immune suppressive features compared to tumors in the gastro-esophageal junction or stomach which might explain the location-specific responses to checkpoint inhibitors in this disease. These findings provide an important rationale for stratification according to tumor location in clinical studies and the development of location-dependent immunomodulatory treatment approaches.
远端食管(EAC)、胃食管交界处(包括贲门)和胃(GAC)的肿瘤在解剖位置上接近,且在分子和细胞水平上具有很强的相似性。然而,最近的临床数据表明,化疗免疫治疗的有效性仅限于一部分 GEJAC 患者,而 EAC 和 GEJAC 与 GAC 相比,通常从检查点抑制中获益较少。由于肿瘤免疫微环境的组成决定了对(免疫)治疗的反应,因此我们在此对大量未经治疗的 GEAC 进行了详细的免疫分析,以促进更个体化的免疫调节策略的发展。
在一项前瞻性研究中,通过 14 色流式细胞术对未经治疗的胃食管癌(n=104)进行了广泛的免疫表型分析,使用了 35 例 EAC、38 例 GEJAC 和 31 例 GAC 的新鲜肿瘤活检。通过免疫表型分析对 GEJAC 的免疫细胞组成进行了描述,并与肿瘤位置、微卫星不稳定性(MSI)和 HER2 状态等临床病理特征相关联。通过多重免疫组化(mIHC)评估了一部分肿瘤的空间免疫结构(n=30),这使我们能够确定 CD3+、CD8+、FoxP3+、CD163+和 Ki67+细胞的肿瘤浸润状态。
免疫表型分析表明,GEJAC 的肿瘤免疫微环境是异质的,与 GAC 相比,单核细胞来源的髓系抑制细胞(mMDSC)等免疫抑制细胞群体在 EAC 中更为丰富(p<0.001)。相反,GAC 表现出炎症前的微环境,增殖(Ki67+)CD4 Th 细胞(p<0.001)、Ki67+CD8 T 细胞(p=0.002)和 CD8 效应记忆-T 细胞(p=0.024)的频率升高。mIHC 分析证实了 EAC 和 GAC 之间的差异,EAC 中肿瘤和基质浸润的 Ki67+CD8 T 细胞密度明显低于 GAC(均为 p=0.021)。
这项对未经治疗的大量 GEAC 进行的全面免疫表型研究表明,与胃食管交界处或胃中的肿瘤相比,具有食管肿瘤位置的肿瘤具有更多的免疫抑制特征,这可能解释了该疾病中检查点抑制剂的位置特异性反应。这些发现为临床研究中根据肿瘤位置进行分层以及开发基于位置的免疫调节治疗方法提供了重要的理论依据。